These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 17495131)

  • 1. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Walsby E; Walsh V; Pepper C; Burnett A; Mills K
    Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
    Nair JS; de Stanchina E; Schwartz GK
    Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.
    Ikezoe T; Yang J; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H
    Mol Cancer Ther; 2007 Jun; 6(6):1851-7. PubMed ID: 17541033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
    Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
    Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Aurora B kinase in non-Hodgkin lymphoma.
    Ikezoe T; Takeuchi T; Yang J; Adachi Y; Nishioka C; Furihata M; Koeffler HP; Yokoyama A
    Lab Invest; 2009 Dec; 89(12):1364-73. PubMed ID: 19823168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
    Tomita M; Tanaka Y; Mori N
    Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.
    Ikezoe T; Yang J; Nishioka C; Yokoyama A
    Int J Hematol; 2010 Jan; 91(1):69-77. PubMed ID: 20013323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
    Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
    Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
    Tao Y; Leteur C; Calderaro J; Girdler F; Zhang P; Frascogna V; Varna M; Opolon P; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Cell Cycle; 2009 Oct; 8(19):3172-81. PubMed ID: 19755861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
    Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
    Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
    Payton M; Cheung HK; Ninniri MSS; Marinaccio C; Wayne WC; Hanestad K; Crispino JD; Juan G; Coxon A
    Mol Cancer Ther; 2018 Dec; 17(12):2575-2585. PubMed ID: 30266802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
    Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
    Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.